

In the Specification:

✓ Please replace the paragraph beginning at page 29, line 5, with the following: ✓

01 --A mimetic for the sequence HTyr-Gly-Gly-Phe (SEQ ID NO:1), which is found in the enkephalins, was synthesized with a  $\alpha$ -turn mimetic based on the Tyr-Gly-Gly tripeptide. Similar mimetics have shown activity at opiate receptors (Huffman, Callahan *et al.*, 1988; Huffman *et al.*, 1989).--

Qm 2 Please insert the accompanying paper copy of the Sequence Listing, page number 1, at the end of the application.

REMARKS

Applicants assert that the sequence on page 29, line 5, is the only peptide sequence which is required to be included in the Sequence Listing. According to 37 C.F.R. §1.821(a), "...amino acid sequences as used in §§1.821 through 1.825 are interpreted to mean an unbranched sequence of four or more amino acids...Sequences with fewer than four specifically defined...amino acids are specifically excluded from this section. "Specifically defined" means those amino acids other than "Xaa"...defined in accordance with the World Intellectual Property Organization (WIPO) Handbook on Industrial Property Information and Documentation, Standard ST.25: Standard for the Presentation of Nucleotide and Amino Acid Sequence Listings in Patent Applications (1998), including Tables 1 through 6 in Appendix 2...". Therefore, the amino acid tripeptides on page 3, lines 16-17; page 29, line 7; page 43, line 31; page 47, line 30; and page 48, line 22, do not satisfy the criteria of having more than four amino acids. Similarly, the amino acid sequence "Ac-Arg-Gly-Asp-Ser-NH<sub>2</sub>" on page 48, lines 15 and 20, contain modified amino acid residues (*i.e.*, N-acetyl-arginine (Ac-Arg) and serinamide (Ser-NH<sub>2</sub>)), which do not fulfill the requirement for specifically defined

amino acids other than Xaa. For these reasons, these amino acid sequences were not included in the Sequence Listing.

Applicants request entry of this amendment in adherence with 37 C.F.R. §§1.821 to 1.825. This amendment is accompanied by a floppy disk containing the above named sequence, SEQ ID NO:1, in computer readable form, and a paper copy of the sequence information which has been printed from the floppy disk.

The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the Specification by the current Amendment. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

Joel G. Ackerman  
Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: (415) 576-0300  
JGA:dmw  
SF 1396961 v1

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 5 of page 29 has been amended as follows:

A mimetic for the sequence HTyr-Gly-Gly-Phe (SEQ ID NO:1), which is found in the enkephalins, was synthesized with a  $\beta$ -turn mimetic based on the Tyr-Gly-Gly tripeptide. Similar mimetics have shown activity at opiate receptors (Huffman, Callahan *et al.*, 1988; Huffman *et al.*, 1989).

TOWNSEND  
*and*  
TOWNSEND  
*and*  
CREW  
LLP